Insights into the structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 6, 2001, Pages 685-695

  Roth, Bryan L ^a   Shapiro, David A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic agents; Anxiolytics; Obsessive compulsive disorder; Serotonin; Structure

Indexed keywords

EID: 0000819514     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.5.6.685     Document Type: Review

References (131)

1. HOYER D, MARTIN G: 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology (1997) 36:419-428.
2. ROTH BL, LOPEZ E, PATEL S, KROEZE W: Multiplicity of serotonin receptors: useless diverse molecules or an embarrassement of riches? The Neuroscientist (2000) 6:252-262.
3. ROTH BL, MELTZER H: The role of serotonin in schizophnrenia. In: Psychopharmocology: The Fourth Generation of Progress. Bloom F, Kupfer D (Eds.), Raven Press, (1995):1215-1227.
4. KROEZE WK, ROTH BL: The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychia. (1998) 44:1128-1142.
5. MAES M, MELTZER H: The role of serotonin in depression. In: Psychopharmacology: a Fourth Generation of Progress. Edited by; 1994
6. 1B receptors. Neuropsychopharmacology (1999) 21:52S-60S.
7. CHARNEY DS, GOODMAN WK, PRICE LH, WOODS SW, RASMUSSEN SA, HENINGER GR: Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch. Gen. Psych. (1988) 45:177-185.
8. 2C serotonin receptors. Nature (1995) 374:542-546.
9. CROWELL MD: The role of serotonin in the pathophysiology of irritable bowel syndrome. Am. J. Manag. Care (2001) 7:S252-260.
10. WHORWELL PJ: Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards. Gut (2001) 48:596-597.
11. FOZARD JR, KALKMAN HO: 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedeberg Arch. Pharmacol. (1994) 350:225-229.
12. HASLER WL: Serotonin receptor physiology: relation to emesis. Dig. Dis. Sci. (1999) 44:108S-113S.
13. SUMPTON JE, MOULIN DE: Treatment of neuropathic pain with venlafaxine. Ann. Pharmacother. (2001) 35:557-559.
14. ATTAL N: Pharmacologic treatment of neuropathic pain. Acta Neurol. Belg. (2001) 101:53-64.
15. 3 receptors. Eur. J. Pharmacol. (2000) 409:167-172.
16. (2C) receptor mutant mice. Psychopharmacology (Berl.) (1999) 143:309-314.
17. POLLOCK BG, MULSANT BH: Behavioral disturbances of dementia. J. Geriatr. Psychia. Neurol. (1998) 11:206-212.
18. 2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J. Neural Transm. (1999) 106:123-129.
19. APTER JT, ALLEN LA: Buspirone: future directions. J. Clin. Psychopharmacol. (1999) 19:86-93.
20. ROTH BL, WILLINS DL, KROEZE WK: G-protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Drug Alcohol. Depend. (1998) 51:73-85.
21. ROTH BL, WILLINS DL, KRISTIANSEN K, KROEZE WK: 5-Hydroxytryptamine2-family receptors (5-hydroxytrypramine2A, 5- hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol. Ther. (1998) 79:231-257.
22. 2A receptors in atypical antipsychotic drug actions. The Neuroscientist (1999) 5:254-262.
23. MELTZER HY: Outcome in schizophrenia: beyond symptom reduction. J. Clin. Psychiatry (1999) 60:3-7.
24. BLAZER DG, KESSLER RC, MCGONAGLE KA, SWARTZ MS: The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry (1994) 151:979-986.
25. BAKER RA, ANDREW MJ, SCHRADER G, KNIGHT JL: Preoperative depression and mortality in coronary artery bypass surgery: preliminary findings. ANZ J. Surg. (2001) 71:139-142.
26. CARNEY RM, FREEDLAND KE, JAFFE AS: Depression as a risk factor for coronary heart disease mortality. Arch. Gen. Psych. (2001) 58:229-230.
27. VACCARINO V, KASL SV, ABRAMSON J, KRUMHOLZ HM: Depressive symptoms and risk of functional decline and death in patients with heart failure. J. Am. Coll. Cardiol. (2001) 38:199-205.
28. JEFFERY RW: Public health strategies for obesity treatment and prevention. Am. J. Health Behav. (2001) 25:252-259.
29. STYNE DM: Childhood and adolescent obesity. Prevalence and significance. Pediatr. Clin. North Am. (2001) 48:823-854.
30. CONNOLLY HM, MCGOON MD: Obesity drugs and the heart. Curr. Probl. Cardiol. (1999) 24:745-792.
31. MELTZER HY, MATSUBARA S, LEE JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Therap. (1989) 251:238-246.
32. MARTIN BC, MILLER LS, KOTZAN JA: Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr. Res. (2001) 47:281-292.
33. FRANGOU S, LEWIS M: Atypical antipsychotics in ordinary clinical practice: a pharmaco- epidemiologic survey in a south London service. Eur. J. Psychiatry (2000) 15:220-226.
34. WETTERLING T: Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. (2001) 24:59-73.
35. MELTZER HY: Suicide in schizophrenia: risk factors and clozapine treatment. J. Clin. Psychiatry (1998) 59:15-20.
36. MELTZER HY, OKAYLI G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry (1995) 152:183-190.
37. MELTZER HY: Clozapine: clinical advantages and biological mechanisms. In: Schizophrenia: A scientific focus. Schulz SC, Tamminga C (Eds.), Oxford University Press, (1989):302-309
38. 2C receptor. Psychopharmacology (Berl.) (1996) 126:234-240.
39. SANCHEZ C, HYTTEL J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol. Neurobiol. (1999) 19:467-489.
40. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology (1997) 36:793-802.
41. 2C receptors: a comparison with citalopram. Eur. J. Neurosci. (2000) 12:1079-1095.
42. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. (1998) 286:913-924.
43. ROTH BL: Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry (1994) 6:67-78.
44. LIGHTOWLER S, WOOD M, BROWN T et al.: An investigation of the mechanism responsible for fluoxerine-induced hypophagia in rats. Eur. J. Pharmacol. (1996) 296:137-143.
45. CURZON G, GIBSON EL, OLUYOMI AO: Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol. Sci. (1997) 18:21-25.
46. CONNOLLY J, VERNI C, TRILLING J, KELSO E, SHIESHA S: Selections from current literature: pharmacological treatment of obesity. Fam. Pract. (1998) 15:88-93.
47. (2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. (2000) 57:75-81.
48. (2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102:2836-2841.
49. 2 receptors. Mol. Pharmacol. (1993) 43:755-761.
50. 2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding [published erratum appears in Mol. Pharmacol. (1995) 48(3):568].
51. Mol. Pharmacol. (1995) 47:450-457.
52. (2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol. Pharmacol. (2000) 58:877-886.
53. 2A receptors. Mol. Pharmacol. (1997) 52:259-266.
54. 2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol. Pharmacol. (1996) 50:34-42.
55. 2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J. Biol. Chem. (1996) 271:14672-14675.
56. 2A serotonin receptor. Bioorg. Med. Chem. Lett. (2001) 11:563-566.
57. RUNYON SP, SAVAGE JE, TAROUA M, ROTH BL, GLENNON RA, WESTKAEMPER RB: Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. Bioorg. Med. Chem. Lett. (2001) 11:655-658.
58. 2A receptor. Eur. J. Med. Chem. (1999) 34:441-447.
59. 2A serotonin receptor but does not participate in activation via a 'salt-bridge disruption' mechanism. J. Pharmacol. Exp. Ther. (2000) 293:735-746.
60. WANG CD, GALLAHER TK, SHIH JC: Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Mol. Pharmacol. (1993) 43:931-940.
61. PALCZEWSKI K, KUMASAKA T, HORI T et al.: Crystal structure of rhodopsin: A G-protein-coupled receptor. Science (2000) 289:739-745.
62. 2A receptor: the third intracellular loop is alpha- helical and binds purified arrestins. J. Neurochem. (1999) 72:2206-2214.
63. 1C serotonin receptors. Mol. Pharmacol. (1992) 42:627-633.
64. 2C receptor interactions. Eur. J. Pharmacol. (1996) 306:195-210.
65. KRISTIANSEN KD, SG, EDVARDSEN, O: A database of mutants and effects of site-directed mutagenesis experiments on G-protein-coupled receptors. In: PROTEINS: Structure, function and genetics (Volume 26). Tromso, Norway: Institute of Medical Biology, University of Tromso (1996):81-94.
66. 2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. (1986) 16:517-525.
67. 2 binding affinity. Neuropsychopharmacology (1988) 1:101-107.
68. 2 antagonistic properties. J. Pharmacol. Exp. Ther. (1988) 244:685-693.
69. KANE J, HONIGFIELD G, SINGER J, MELTZER HY: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psy. (1988) 45:789-796.
70. BYMASTER FC, FALCONE JF MARSH RD: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology (1996) 14:87-96.
71. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl.) (1995) 120:365-368.
72. SALLER CF, SALAMA AI: Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (1993) 112:285-292.
73. SEEGER TF, SEYMOUR PA, SCHMIDT AW et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. (1995) 275:101-113.
74. 1A receptors in human brain tissue. Eur. J. Pharmacol. (1992) 221:397-398.
75. 1A receptor activation. Eur. J. Pharmacol. (1997) 338:R3-R5.
76. 35S]GTPgammaS binding study. Eur. J. Pharmacol. (1998) 355:245-256.
77. 1C receptors. J. Pharmacol. Exp. Ther. (1992) 260:1361-1365.
78. ROTH BL, CRAIGO SC, CHOUDHARY MS et al.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. (1994) 268:1403-1410.
79. 4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610-614.
80. 35S]GTPgammaS binding assays. Naunyn Schmiedebergs Arch. Pharmacol. (2000) 361:498-504.
81. BOLDEN C, CUSACK B, RICHELSON E: Antagonism by anitmuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in chinese hamster ovary cells. J. Pharmacol. Exp. Therap. (1992) 260:576-580.
82. ZENG XP, LE F, RICHELSON E: Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. (1997) 321:349-354.
83. ROTH B, MELTZER H, KHAN N: Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. In Advances in Pharmacology (Volume 42). Goldstein D, Eisenhoffer G, McCarty R (Eds.) Academic Press, (1998):482-485.
84. 2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemtcal studies. J. Pharmacol. Exp. Ther. (1993) 266:684-691.
85. DE PAULIS T: M-100907 (Aventis). Curr. Opin. Investig. Drugs (2001) 2:123-132.
86. 2/1C antagonist and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry (1993) 163:451-455.
87. CHRISTENSSON E, BJORK A: Amperozide: a new pharmacological approach in the treatment of schizophrenia. Pharmacologie et Toxicologie (1990) 66:5-7.
88. 2 receptor antagonist. Psychopharmacology (Berl.) (1991) 104:287-292.
89. 2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry (1999) 156:419-425.
90. NARENDRAN R, YOUNG CM, VALENTI AM, PRISTACH CA, PATO MT, GRACE JJ: Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J. Clin. Psychiatry (2001) 62:509-516.
91. SANGER TM, GRUNDY SL, GIBSON PJ, NAMJOSHI MA, GREANEY MG, TOHEN MF: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J. Clin. Psychiatry (2001) 62:273-281.
92. GHAEMI SN, CHERRY EL, KATZOW JA, GOODWIN FK: Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. (2000) 2:196-199.
93. LINDSTROM LH: A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology (Berl.) (1989) 99:S84-S86.
94. MCELROY SL, DESSAIN EC, POPE HG, Jr. et al.: Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. J. Clin. Psychiatry (1991) 52:411-414.
95. TAYLOR DM, MCASKILL R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr. Scand. (2000) 101:416-432.
96. MCINTYRE RS, MCCANN SM, KENNEDY SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Can. J. Psychiatry (2001) 46:273-281.
97. FONTAINE KR, HEO M, HARRIGAN EP et al.: Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. (2001) 101:277-288.
98. YAMADA M, MIYAKAWA T, DUTTAROY A et al.: Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature (2001) 410:207-212.
99. WIRSHING DA, WIRSHING WC, KYSAR L et al.: Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychol. (1999) 60: 358-363.
100. 3H]Mianserin: differential labeling of serotonin and histamine receptors in rat brain. J. Pharmacol. Exp. Ther. (1981) 216:142-148.
101. LANGER SZ: 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol. Sci. (1997) 18:95-99.
102. ABED RT, COOPER M: Mirtazepine causing hyperphagia. Br. J. Psychiatry (1999) 174:181.
103. 2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl.) (1995) 119:222-230.
104. SCOTT JA, CREWS FT: Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors. Neuropharmacology (1986) 25:1301-1306.
105. 2C receptors. Neuropharmacology (1994) 33:467-471.
106. 2C/2B receptor antagonist. Br. J. Pharmacol. (1994) 111:797-802.
107. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl.) (1994) 114:90-96.
108. GRIEBEL G: 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. (1995) 65:319-395.
109. BENJAMIN J, GREENBERG BD, MURPHY DL: Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology (Berl.) (1996) 127:140-149.
110. 2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology (2001) 41:186-199.
111. 2C receptor inverse agonists with potential as antidepressant/anxiolytic agents. Bioorg. Med. Chem. Lett. (2000) 10:1863-1866.
112. DELGADO PL, MORENO FA: Hallucinogens, serotonin and obsessive-compulsive disorder. J. Psychoactive Drugs (1998) 30:359-366.
113. PERRINE DM: Hallucinogens and obsessive-compulsive disorder. Am. J. Psychiatry (1999) 156:1123.
114. BRANDRUP E, VANGGAARD T: LSD treatment in a severe case of compulsive neurosis. Acta Psychiatry Scand. (1977) 55:127-141.
115. CHOUINARD G: Sertraline in the treatment of obsessive-compulsive disorder: two double; blind placebo-controlled studies. Int. Clin. Psychopharmacol. (1992) 7:37-41.
116. DAGOGO-JACK S: Human leptin regulation and promise in pharmacotherapy. Curr. Drug Targets (2001) 2:181-195.
117. PROIETTO J, FAM BC, AINSLIE DA, THORBURN AW: Novel anti-obesity drugs. Expert Opin. Investig. Drugs (2000) 9:1317-1326.
118. VERGONI AV, BERTOLINI A: Role of melanocortins in the central control of feeding. Eur. J. Pharmacol. (2000) 405:25-32.
119. WARDEN NA, WARDEN CH: Biological influences on obesity. Pediatr. Clin. North Am. (2001) 48:879-891.
120. WILDING J: The future of obesity treatment. EXS (2000) 89:181-191.
121. GLAZER G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch. Intern. Med. (2001) 161:1814-1824.
122. MICHELAKIS ED, WEIR EK: Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am. J. Med. Sci. (2001) 321:292-299.
123. MCCANN UD, YUAN J, RICAURTE GA: Neurotoxic effects of +/-fenfluramine and phenteramine, alone and in combination, on monoamine neurons in the mouse brain. Synapse (1998) 30:239-246.
124. 2C receptors in CHO-K1 cells. Br. J. Pharmacol. (1999) 128:13-20.
125. DOURISH CT: Multiple serotonin receptors: opportunities for new treatments for obesity? Obes. Res. (1995) 3 (Suppl. 4):449S-462S.
126. 1B receptor. Science (1994) 265:1875-1878.
127. PIGOTT TA, HILL JL, GRADY TA et al.: A comparison of the behavioral effects of oral verses intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol. Psychia. (1993) 33:3-14.
128. LYDIARD RB, BRAWMAN-MINTZER O, BALLENGER JC: Recent developments in the psychopharmacology of anxiety disorders. J. Consult. Clin. Psychol. (1996) 64:660-668.
129. BLIER P, ABBOTT FV: Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci. (2001) 26:37-43.
130. 1D binding sites. Eur. J. Pharmacol. (1989) 163:133-136.
131. SALZMAN C: Treatment of the agitation of late-life psychosis and Alzheimer's disease. Eur. Psychiatry (2001) 16(Suppl. 1):25-28.